Agreements

Date: 2015-05-20

Type of information: Collaboration agreement

Compound: LISA-TRACKER’s infliximab monitoring kit

Company: Theradiag (France) Hospira (USA - IL)

Therapeutic area: Autoimmune diseases - Dermatological diseases - Inflammatory diseases - Digestive diseases - Rheumatic diseases

Type agreement: collaboration

Action mechanism: theranostic test

Disease: rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis

Details:

• On May 20, 2015, Theradiag, a company specializing in theranostics and in vitro diagnostics, announced that it has entered into a partnership agreement with Hospira regarding the supply of LISA-TRACKER’s CE-marked infliximab monitoring kit. To give clinicians and patients the highest level of biological information regarding the treatment with the biosimilar of infliximab, Hospira will be providing LISA TRACKER’s infliximab assays and anti-infliximab antibodies assays kits in tenders awarded in Europe, Canada and Australia. Hospira has selected Theradiag as its exclusive provider of monitoring tools.
Theradiag will supply Hospira with LISA TRACKER monitoring kits and will also ensure installation and training in laboratories and provide information and follow-up with clinicians on behalf of Hospira. LISA TRACKER’s infliximab kits have been validated for use with Inflectra®.
Hospira commercializes Inflectra®, the first biosimilar monoclonal antibody to be approved by the European Medicines Agency. It is a biologic equivalent to infliximab (Remicade®), which is indicated for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis. Remicade® generated 10.1 billion dollars worldwide sales in 2014.

Financial terms:

Latest news: